Fineimmu announced that it has received nearly CNY 100,000,000 in its pre-series A round of funding led by Huafang Investment on August 3, 2022. The transaction included participation from Yabao Pharmaceutical Group Co., Ltd and Panacea Venture Management Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.71 CNY | -0.87% |
|
+1.06% | -17.25% |
1st Jan change | Capi. | |
---|---|---|
-17.25% | 566M | |
+23.59% | 44.09B | |
+30.04% | 23.18B | |
+21.36% | 15.66B | |
+18.40% | 14.35B | |
+62.51% | 13.2B | |
-0.05% | 6.79B | |
-11.78% | 6.45B | |
-8.87% | 5.73B | |
+14.11% | 5.63B |
- Stock Market
- Equities
- 600351 Stock
- News Yabao Pharmaceutical Group Co., Ltd
- Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor